PinnyPeptide

ACTH 1-39 (Corticotropin) vs Pinealon

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

ACTH 1-39 (Corticotropin)

Cognitive

Full-length adrenocorticotropic hormone — endocrine research peptide, melanocortin agonist.

Peptide B

Pinealon

Cognitive

Neuroprotective tripeptide bioregulator that penetrates the nuclear membrane to directly regulate gene expression in brain tissue.

Typical vial

5 mg

Typical dose

250 (diagnostic) mcg

Half-life

~10-15 minutes (plasma)

FDA status

Cosyntropin (ACTH 1-24) FDA approved as Cortrosyn. Repositor…

Typical vial

20 mg

Typical dose

100-500 mcg

Half-life

~1-2 hours (estimated; formal pharmacokinetic data in humans is not published — biological effects on gene expression persist beyond plasma clearance)

FDA status

Not FDA approved. No IND or NDA has been submitted to the FD…

ACTH 1-39 (Corticotropin) effects

  • Stimulates adrenal cortex to release cortisol
  • Activates MC2R on adrenocortical cells (primary)
  • Secondary activation of MC1R (pigmentation), MC3-5R
  • Used diagnostically to assess adrenal function
  • Anti-inflammatory effects via cortisol release

Pinealon effects

  • Suppresses reactive oxygen species (ROS) accumulation in neuronal cells, reducing oxidative stress-driven cell death
  • Preserves dendritic spine morphology in models of Alzheimer's and Huntington's disease, protecting synaptic integrity
  • Modulates gene expression via direct nuclear membrane penetration, regulating genes involved in neuronal survival (SOD2, GPX1, CASP3, APOE)
  • Supports serotonin biosynthesis by promoting 5-tryptophan hydroxylase expression, with potential mood-regulatory effects
  • Reduces apoptotic signaling in neurons by downregulating pro-apoptotic proteins including caspase-3
  • Reported improvement in memory, cognitive performance, and reduced headache duration in patients with traumatic brain injury sequelae

ACTH 1-39 (Corticotropin) side effects

  • All side effects of pharmacological hypercortisolism: hyperglycemia, weight gain, mood changes, immunosuppression, hypertension
  • Hyperpigmentation with chronic use (MC1R activation)
  • HPA axis suppression with prolonged dosing
  • Acne, fluid retention
  • Adrenal hyperplasia with chronic stimulation

Pinealon side effects

  • Injection site reactions: mild redness, itching, or transient swelling at subcutaneous injection site
  • Headache or mild dizziness, particularly early in a dosing cycle
  • Vivid dreams or mild sleep disturbance if administered late in the day (likely related to CNS activity)
  • Gastrointestinal discomfort (more commonly reported with oral capsule form)
  • Rare: transient mild anxiety or fatigue; allergic hypersensitivity reactions are possible but not well-documented in the literature

ACTH 1-39 (Corticotropin) dosing ranges

Adrenal stimulation test (clinical)

250 mcg · Single IV or IM dose · Diagnostic, one-time

Endocrine research

Variable · Per study protocol · Per study protocol

Pinealon dosing ranges

Cognitive support and neuroprotection (subcutaneous)

100-500 mcg · Once daily · 10-20 days per cycle, repeated 2-4 times per year

Traumatic brain injury sequelae / cerebral asthenia (oral, clinical study protocol)

0.2 mg (200 mcg) twice daily · Twice daily · 20-30 days

General anti-aging and brain longevity (oral supplement)

10-20 mg per day (1-2 capsules of 10 mg each) · Once or twice daily, 30 minutes before meals · 1 month on, then reassess

Full ACTH 1-39 (Corticotropin) guide → Full Pinealon guide →

ACTH 1-39 (Corticotropin) vs Pinealon — common questions

What is the difference between ACTH 1-39 (Corticotropin) and Pinealon?

ACTH 1-39 (Corticotropin): Full-length adrenocorticotropic hormone — endocrine research peptide, melanocortin agonist. Typical dose 250 (diagnostic) mcg. Pinealon: Neuroprotective tripeptide bioregulator that penetrates the nuclear membrane to directly regulate gene expression in brain tissue. Typical dose 100-500 mcg. Both fall under the Cognitive category.

Can you stack ACTH 1-39 (Corticotropin) and Pinealon?

Stacking ACTH 1-39 (Corticotropin) with Pinealon is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, ACTH 1-39 (Corticotropin) or Pinealon?

ACTH 1-39 (Corticotropin) is typically dosed: Single IV or IM dose for Adrenal stimulation test (clinical); Per study protocol for Endocrine research. Pinealon is typically dosed: Once daily for Cognitive support and neuroprotection (subcutaneous); Twice daily for Traumatic brain injury sequelae / cerebral asthenia (oral, clinical study protocol); Once or twice daily, 30 minutes before meals for General anti-aging and brain longevity (oral supplement).

Are ACTH 1-39 (Corticotropin) and Pinealon FDA approved?

ACTH 1-39 (Corticotropin): Cosyntropin (ACTH 1-24) FDA approved as Cortrosyn. Repository ACTH (porcine, full-length) FDA approved as Acthar Gel for infantile spasms, MS exacerbations, and other indications. Pinealon: Not FDA approved. No IND or NDA has been submitted to the FDA. Classified as a research chemical in the United States.

Related peptide comparisons

acth-1-39 vs adamaxacth-1-39 vs dermorphinacth-1-39 vs pnc-27acth-1-39 vs selankacth-1-39 vs semaxadamax vs pinealon

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free